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cluded drug acquisition, supply and labour costs (in 1998
Canadian dollars). RESULTS: Two days of IV therapy
cost $57.48, $78.51 and $82.52, for azithromycin, eryth-
romycin, and cefuroxime, respectively. The total cost of a
10-day course of therapy was $136.36 for azithromycin
and $165.58 for cefuroxime  erythromycin ($126.36
for cefuroxime alone and $208.07 for cefuroxime 
erythromycin). Approximately 280 CAP patients were
seen at our institution in 1996, translating into potential
cost savings of $8,182 per year with azithromycin. CON-
CLUSION: Azithromycin IV/PO is a cost-effective alter-
native for in-patient treatment of CAP.
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OBJECTIVE: This study outlines the management strat-
egy used to treat ribavirin-induced hemolytic anemia
(RIHA) when used in combination therapy in the treat-
ment of chronic hepatitis C (CHC). It also estimates the
direct cost of treating RIHA per treatment course.
METHODS: A systematic review of the literature (1991–
1999) was conducted to abstract information on the fre-
quency and management of RIHA in the treatment of
CHC. Costs were obtained from a large private health in-
surance database from the state of Washington, and from
Drug Topics Red Book. Decision analytic techniques
were used to develop a model (base case) that estimated
the cost of RIHA. Additionally, several one-way sensitiv-
ity analyses, best and worst cases, and two additional
clinical scenarios were simulated with the model. RE-
SULTS: RIHA occurs in approximately 8% of those
treated for CHC. Standard of care dictates management
by dosage reduction or discontinuation of the ribavirin
component of therapy. The decrease in effectiveness of
therapy, as a result of this reduction/discontinuation, has
not been studied. We estimate the direct cost of treating
RIHA at $170 per patient per 48-week treatment course.
The cost ranges from $68 to $692 in the best and worst
case scenarios, respectively. CONCLUSIONS: RIHA is
an anticipated side effect of therapy for CHC. Manage-
ment of RIHA is simple and effective, however its impact
on overall treatment effectiveness is not known. The di-
rect cost of treating RIHA is low, although the likely de-
crease in effectiveness may increase indirect costs over
time, and deserves further study.
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Pneumonia was the third leading admitting diagnosis at a
large tertiary care hospital costing $12,653 per admis-
sion. The American Thoracic Society recommends the
use of a -lactam with or without macrolide as the pre-
ferred antimicrobial regimen for patients with CAP ad-
mitted to a non-ICU. OBJECTIVE: The objective of this
evaluation was to compare ceftriaxone alone (regimen 1)
versus ceftriaxone plus macrolide (regimen 2) using
length of stay, antibiotic costs, and total hospital charges
from a hospital perspective. METHODS: The data were
collected prospectively during December 1998 and May
1999. Fine et al 1998 defined risk scores for CAP and
classified them into 5 categories: 1 (low risk) through 5
(high risk). Most of our patient population belonged to
risk class 2. We compared 26 patients diagnosed with
CAP and stratified into risk class 2. Thirteen patients re-
ceived regimen 1 and 13 patients received regimen 2. RE-
SULTS: We found statistically significant differences in
hospital length of stay, antibiotic costs, and total hospital
charges. Patients who received ceftriaxone alone had
shorter lengths of stay (2.7  1.9 days vs. 5.6  3.9 days,
P  0.028), lower antibiotic costs ($93.02  $58.79 vs.
$169.11  $108.81, P  0.036), and lower total hospi-
tal charges per patient ($2,362.41  $1,442.18 vs.
$4,431.42  $3,108.92, P  0.040) than patients who
received ceftriaxone plus macrolide. CONCLUSION:
Ceftriaxone alone may be sufficient in the treatment of
hospitalized CAP patients who are classified in risk class 2.
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The seven-valent pneumococcal conjugate vaccine (PCV)
is the only vaccine to immunize children under two years
old against Streptococcus Pneumoniae, a leading cause of
meningitis, bacteremia, pneumonia, otitis media, and si-
nusitis. OBJECTIVE: The purpose of this analysis is to
assess the cost-effectiveness of PCV in Canada, the
United Kingdom, France, Germany, Italy, and Spain.
METHODS: A Markov cohort simulation model was
constructed to compare the health and economic out-
comes of children vaccinated with PCV versus unvacci-
nated. Estimated disease-specific incidence and mortality
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rates for each country, as well as relative risk rates for
vaccinated children, were entered into the model. Pri-
mary research was used in Canada, Germany, and the
United Kingdom to establish incidence rates for the
model. Incidence data for other countries was obtained
from published studies. Relative risk data for vaccination
was obtained from the Northern California Kaiser Per-
manente Efficacy Study. The following “health states”
were considered in the model: well, meningitis, bactere-
mia, pneumonia, otitis media, sinusitis, and death. A de-
cision tree model was developed for each “health state”
in each country, to evaluate the direct and indirect cost of
illness. Each decision tree model was based on a local
clinical management analysis and resource valuation. The
Markov model was adapted to accommodate five dosing
schedules of PCV, based on the age of initial vaccination.
The expected utilization of PCV in all child groups was
incorporated in a net budgetary impact analysis. RE-
SULTS: Cost-effectiveness, measured as the incremental
cost-per-life-year gained, varied by country. PCV is a
cost-effective method of disease prevention when consid-
ering the savings in direct and indirect costs and the high
efficacy demonstrated in invasive disease. CONCLU-
SIONS: PCV should be supported by healthcare provid-
ers in the six countries because it is the only means of
pneumococcal disease prevention in a high-risk popula-
tion and it is cost-effective.
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OBJECTIVE: To estimate the clinical and economic ben-
efits of the pneumoccocal conjugate vaccine (PCV) in
preventing acute otitis media (AOM), tympanostomy, and
community-acquired pneumonia (CAP) (“study events”)
in young children. METHODS: We developed a model of
the incidence to age 10 years of study events in children
5 years of age, and used it to examine the benefits of
vaccination in a hypothetical cohort of 1000 children.
We estimated the cumulative incidence and medical-care
costs (discounted at 3%) of study events in the absence of
vaccination using data from a large health plan; indirect
costs were not considered. Among children vaccinated at
ages 2 years, vaccination was assumed to reduce the
annual number of cases of AOM by 7% to age 2 years,
by 9.6% between ages 2–5 years, and by 4.8% thereafter.
Among children vaccinated at ages 24–59 months, the
AOM rate was assumed to be reduced by 9.6% for 3
years, and by 4.8% thereafter. Vaccination was similarly
assumed to reduce the annual rate of tympanostomy and
CAP by 20% and 11% respectively to age 5 years among
children vaccinated at ages 2 years, and for 3 years for
those vaccinated at ages 24–59 months; thereafter, pro-
tective efficacy was assumed to be 10% and 5.5% respec-
tively. RESULTS: Vaccination would reduce the cumula-
tive incidence of AOM (to age 10 years) by 163–376 cases
per 1000 children, tympanostomy by 8–22 cases per 1000,
and CAP by 14–31 cases per 1000. Total cumulative dis-
counted medical-care costs would be reduced by $30,000–
$74,000 per 1000. CONCLUSION: Routine vaccination
of young children with PCV would reduce the incidence
and costs of AOM, tympanostomy, and CAP.
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OBJECTIVE: Although efavirenz has demonstrated excel-
lent efficacy in clinical trials and is less expensive than most
regimens, a full understanding of its economic impact re-
quires knowledge of the effect key parameters have on the
economic situation. In this study, the costs of managing
HIV treatment naïve patients with efavirenz compared to
indinavir were evaluated. METHODS: A model was devel-
oped to simulate the disease progression of a population of
HIV patients. Data from a clinical trial comparing two
nucleoside reverse transcriptase inhibitors plus efavirenz to
a similar regimen containing indinavir provided effective-
ness inputs to the model. These data along with the likeli-
hood of viral rebound over time were used to project the
long-term effectiveness of initial treatment with these regi-
mens. Cost estimates were developed from six all-payer
state discharge databases, fee schedules, survey data and
the literature for different disease states in the progression
of HIV. Costs are reported in 1998 US dollars. RESULTS:
Over the 24 week trial period, patients beginning treatment
with an efavirenz regimen were predicted to cost $2672 less
than those started on an indinavir regimen. Efavirenz is
forecast to maintain cost savings through year 6 ($11,015)
given its intention-to-treat response rate of 75%. Only if
this rate were 30% of the demonstrated rate would indi-
navir therapy be less expensive over the first 3.2 years fol-
lowing treatment initiation at which time efavirenz
achieves cost savings. Other factors such as the cost of indi-
navir therapy will be discussed. CONCLUSIONS: The re-
sults of our model suggest that the health benefits associ-
ated with efavirenz treatment are achieved at a cost savings
relative to indinavir treatment. These results were found to
be quite robust to variation in key parameters.
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